WHO MEDICINES STRATEGY 2004-2007 | 146
REFERENCES | 1471Annual report 2000, Essential Drugs and Medicines Policy. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>,2001 (WHO/EDM/2001.4); Annual report 2001, Essential Drugs and Medicines Policy: Extending theevidence base. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 2002 (WHO/EDM/2002.1); Annual report 2002,Essential Drugs and Medicines Policy: Supporting countries to close the access gap. Geneva, <strong>World</strong><strong>Health</strong> <strong>Organization</strong>, 2003 (WHO/EDM/2003.1).2Essential drugs in brief. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>. Journal issued three times per year.3<strong>World</strong> <strong>Health</strong> Assembly Resolutions Revised drug <strong>strategy</strong> (A53/10 and A54/17) and WHO <strong>medicines</strong><strong>strategy</strong> (A55/12 and A56/16).4How to develop and implement a national drug policy. WHO Policy Perspectives on Medicines, No.6.Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 2003 (WHO/EDM/2002.5).5Questionnaire on country pharmaceutical situations. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 2003 (EDM/DAP).6Globalization, TRIPS and access to pharmaceuticals. WHO Policy Perspectives on Medicines, No. 3.Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 2001 (WHO/EDM/2001.2).7Annual report 2002, Essential Drugs and Medicines Policy: Supporting countries to close the access gap.Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 2003 (WHO/EDM/2003.1).8Implications of the Doha Declaration on the TRIPS Agreement and Public <strong>Health</strong>. Geneva, <strong>World</strong> <strong>Health</strong><strong>Organization</strong>, 2002. <strong>Health</strong> Economics and Drugs, EDM Series No. 12 (WHO/EDM/PAR/2002.3).9Annual report 2002. Op. cit.10Troullier P et al. Lancet, 2002, 359:2188-94; Pécoul B et al. Fatal imbalance. The crisis in researchand development for drugs for neglected diseases. Geneva, Médecins Sans Frontièrès. 2001.(www.accessmed-msf.org); Morel CM. Parasitology Today, 2001.11Introducing the gender perspective in national essential drugs programmes. Geneva, <strong>World</strong> <strong>Health</strong><strong>Organization</strong>, 2001 (EDM/DAP/2001.1).12http://www.<strong>who</strong>.<strong>int</strong>/gender/documents/fact/en/13<strong>World</strong> development report 2003. New York, United Nations Development Programme, 2003.14Ethical criteria for medicinal drug promotion. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 1988(http://www.<strong>who</strong>.<strong>int</strong>/<strong>medicines</strong>/library/dap/ethical-criteria/ethicalen.shtml).15Davidoff F et al. Sponsorship, authorship and accountability. Lancet, 2001, 325:854-856 (publishedsimultaneously in 12 other medical journals).16http://www.transparency.org/17http://www.corisweb.org/18WHO traditional medicine <strong>strategy</strong> 2002-2005. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 2002 (WHO/EDM/TRM/2002.1).19<strong>World</strong> <strong>Health</strong> Assembly Resolution 56.31. Traditional medicine.20Legal status of traditional medicine and complementary/alternative medicine. Geneva, <strong>World</strong> <strong>Health</strong><strong>Organization</strong>, 2001 (WHO/EDM/TRM/2001).21Global comparative pharmaceutical expenditures with related reference information. <strong>Health</strong> Economicsand Drugs, EDM Series No.3. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 2000 (EDM/PAR/2000.2).22http://www3.<strong>who</strong>.<strong>int</strong>/<strong>who</strong>sis/cmh/cmh_report/e/pdf/001-004.pdf23<strong>World</strong> <strong>medicines</strong> situation. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong> (In preparation).24<strong>Health</strong> reform and drug financing. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 1998 (WHO/DAP/98.3).25<strong>World</strong> health report 1999: Making a difference. Geneva <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>; 1999; <strong>World</strong>health report 2000; Shaping the future. Geneva <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 2000; Public-private rolesin the pharmaceutical sector. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 1997 (WHO/DAP/97.12).26Global Fund to Fight Aids, Tuberculosis and Malaria (http://www.globalfundatm.org).27<strong>World</strong> Bank HIV/AIDS (http://www1.worldbank.org/hiv_aids/index.asp).28<strong>World</strong> health report 1999: Making a difference. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong>, 1999.29What is WHO doing to improve drug price information? WHO Fact Sheet: Drug Price InformationServices. (http://www.<strong>who</strong>.<strong>int</strong>/<strong>medicines</strong>/organization/par/ipc/drugpriceinfo.shtml).30Medicine prices: a new approach to measurement. Geneva, <strong>World</strong> <strong>Health</strong> <strong>Organization</strong> and <strong>Health</strong>Action International, 2003 (WHO/EDM/PAR/2003.2).31The use of essential drugs Report of the WHO Expert Committee 1997 (including the 10 th Model List